Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide With or Without Stem Cell Transplant in Relapsed/Refractory Multiple Myeloma
NCT01745588Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2012
- Primary completion
- Sep 2025
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pomalidomide in multiple myeloma (MM) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate at 9 months. Started Dec 2012; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01745588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01745588.